Date Filed | Type | Description |
07/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/12/2023 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Sold 100 shares
@ $20, valued at
$2k
|
|
06/08/2023 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Sold 2,143 shares
@ $18.61, valued at
$39.9k
Sold 2,500 shares
@ $19.34, valued at
$48.4k
|
|
06/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/23/2023 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Sold 349 shares
@ $12.89, valued at
$4.5k
Sold 357 shares
@ $12.64, valued at
$4.5k
Sold 372 shares
@ $12.15, valued at
$4.5k
|
|
03/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/17/2023 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Sold 336 shares
@ $13.43, valued at
$4.5k
Exercised 4,790 restricted stock units
@ $0 |
|
03/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/10/2023 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Granted 48,116 options to buy
@ $15, valued at
$721.7k
Granted 32,592 restricted stock units
@ $0 |
|
11/17/2022 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Sold 6,857 shares
@ $17.72, valued at
$121.5k
|
|
08/26/2022 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Exercised 4,416 options to buy
@ $10.99, valued at
$48.5k
Exercised 772 options to buy
@ $0.45, valued at
$347.4 |
|
03/11/2022 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Granted 65,312 options to buy
@ $19.59, valued at
$1.3M
Granted 19,160 restricted stock units
@ $0 |
|
11/10/2021 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Sold 1,889 shares
@ $28.11, valued at
$53.1k
|
|
11/08/2021 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Sold 100 shares
@ $28.03, valued at
$2.8k
Sold 11 shares
@ $28.11, valued at
$309.2 |
|
11/04/2021 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Sold 5,458 shares
@ $26.753, valued at
$146k
Sold 542 shares
@ $27.071, valued at
$14.7k
|
|
09/14/2021 |
4
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 4 on Tarsus Pharmaceuticals, Inc.
Txns:
| Sold 2,593 shares
@ $22.15, valued at
$57.4k
Exercised 4,350 options to buy
@ $10.99, valued at
$47.8k
Exercised 2,593 options to buy
@ $0.45, valued at
$1.2k
|
|
01/08/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/15/2020 |
3
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 3 on Tarsus Pharmaceuticals, Inc. |
09/20/2019 |
3
| Mottiwala Aziz (Chief Commercial Officer) has filed a Form 3 on OPIANT PHARMACEUTICALS, INC. |